^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    EGFR T790M

    i
    Other names: EGFR, ERBB, ERBB1, Epidermal growth factor receptor
    Entrez ID:
    1956
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    Related tests:
    1d
    The Bone Microenvironment and Therapeutic Resistance in Spinal Metastases: Mechanisms and Clinical Implications. (PubMed, J Clin Neurosci)
    The vertebral niche constitutes a treatment-resistant microenvironment where dormant tumor cells persist, immune surveillance is impaired, and resistant clones evolve. Integrating bone-microenvironment biology with molecular profiling, liquid biopsy, and advanced imaging is essential for refining prognostic models, guiding intervention timing, and designing spine-specific clinical trials. By reframing spinal metastases as a biologically and therapeutically distinct disease entity, this review establishes a framework for developing bone-directed treatment strategies and advancing precision oncology in metastatic spine care.
    Review • Journal • BRCA Biomarker
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • BRCA (Breast cancer early onset)
    |
    EGFR mutation • EGFR T790M • ALK mutation • BRCA mutation
    4d
    WSD0922-FU for the Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System Metastases (clinicaltrials.gov)
    P1, N=56, Active, not recruiting, Mayo Clinic | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    EGFR mutation • EGFR L858R • EGFR T790M • EGFR amplification • EGFR L861Q • IDH wild-type
    |
    WSD0922
    6d
    Synthesis of 4-chloro-N'-(2-cyanoacetyl)benzohydrazide derivatives, cytotoxicity, VEGFR-2/EGFRT790M bioassays and in silico docking/ADMET studies. (PubMed, Bioorg Chem)
    Cytotoxic effects on A549 cell lines, compared to sorafenib (4.04 μM) and erlotinib (5.49 μM), showed that compounds 4, 5, 6, 7, 8, 10 and 11 with the IC50 values of 5.50-8.00 μM exhibited very high activities. Molecular docking was carried out for all derivatives to show their binding affinities and orientations inside the active sites of VEGFR-2 and EGFRT790M receptors to support the in vitro results. The data obtained from docking is highly matched with that obtained from biological testing.
    Journal
    |
    KDR (Kinase insert domain receptor)
    |
    EGFR mutation • EGFR T790M
    |
    erlotinib • sorafenib
    7d
    An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=59, Completed, Incyte Corporation | Active, not recruiting --> Completed
    Trial completion
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X
    |
    Tagrisso (osimertinib) • itacitinib (INCB039110)
    7d
    Clinical implications of plasma EGFR T790M and ctDNA shedding across metastatic sites in plasma- or tissue-confirmed EGFR-mutant non-small cell lung cancer treated with lazertinib: a prospective multicenter cohort study. (PubMed, Transl Lung Cancer Res)
    Liver and adrenal metastases occurred exclusively in plasma T790M-positive patients and were associated with markedly worse outcomes, consistent with a ctDNA-shedding phenotype. Bone metastasis was an adverse prognostic factor independent of plasma T790M, underscoring the combined prognostic impact of molecular and metastatic features.
    Journal • Circulating tumor DNA
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR T790M • EGFR positive
    |
    Lazcluze (lazertinib)
    9d
    S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2/3, N=174, Active, not recruiting, SWOG Cancer Research Network | Trial completion date: Nov 2025 --> Dec 2026
    Trial completion date
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M
    |
    Erbitux (cetuximab) • Gilotrif (afatinib)
    10d
    Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial) (clinicaltrials.gov)
    P3, N=390, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Oct 2026 --> Feb 2027 | Trial primary completion date: Oct 2026 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • ALK rearrangement
    |
    erlotinib
    11d
    Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLC (clinicaltrials.gov)
    P1, N=16, Terminated, Rutgers, The State University of New Jersey | Active, not recruiting --> Terminated; accrual goal met
    Trial termination
    |
    BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • LAG3 (Lymphocyte Activating 3) • IDO1 (Indoleamine 2,3-dioxygenase 1) • CD27 (CD27 Molecule)
    |
    BRAF V600E • EGFR mutation • BRAF V600 • EGFR T790M • ALK rearrangement • ROS1 rearrangement
    |
    Tecentriq (atezolizumab) • varlilumab (CDX 1127)
    12d
    HBE-843, a Novel, Potent, and Selective EGFR Targeting PROTAC for the Treatment of Non-Small-Cell Lung Cancer. (PubMed, Arch Pharm (Weinheim))
    In vivo studies demonstrated a 112% tumor growth inhibition in L858R-induced cancers. These findings suggest that HBE-843 holds promise as a lead compound for developing new drugs to overcome C797S mutant-mediated resistance in clinical settings.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • CRBN (Cereblon)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR wild-type
    15d
    TATTON: AZD9291 in Combination With Ascending Doses of Novel Therapeutics (clinicaltrials.gov)
    P1, N=344, Active, not recruiting, AstraZeneca | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M
    |
    Tagrisso (osimertinib) • Imfinzi (durvalumab) • Koselugo (selumetinib) • Orpathys (savolitinib) • simmitinib (SYHA1817)
    16d
    Adjuvant osimertinib following SBRT in patients with unresected EGFRm stage I-II lymph node-negative (T1-3N0M0) NSCLC ： A Phase II, Prospective, Multicenter, Interventional study (SPACE) (ChiCTR2500111875)
    P=N/A, N=60, Not yet recruiting, Shandong First Medical University and Shandong Academy of Medical Sciences (Shandong Cancer Hospital ＆Institute); Shandong First Medical University
    New trial
    |
    CD4 (CD4 Molecule)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M
    |
    Tagrisso (osimertinib) • simmitinib (SYHA1817)
    16d
    Clinical Study of ctDNA Dynamic Monitoring in Sacituzumab tirumotecan for EGFR-Mutated Non-Squamous NSCLC After EGFR-TKI Failure (ChiCTR2600115950)
    P4, N=30, Not yet recruiting, Shaanxi Provincial Cancer Hospital; Shaanxi Provincial Cancer Hospital
    New P4 trial
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M
    |
    Jiataile (sacituzumab tirumotecan)